update
Browse files
app.py
CHANGED
@@ -3,7 +3,7 @@ import gradio as gr
|
|
3 |
|
4 |
openai.api_key = "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"
|
5 |
|
6 |
-
def get_completion_from_messages(messages, model="gpt-3.5-turbo", temperature=0):
|
7 |
response = openai.ChatCompletion.create(
|
8 |
model=model,
|
9 |
messages=messages,
|
@@ -12,11 +12,16 @@ def get_completion_from_messages(messages, model="gpt-3.5-turbo", temperature=0)
|
|
12 |
return response.choices[0].message["content"]
|
13 |
|
14 |
def get_response(text):
|
15 |
-
messages = [
|
16 |
-
{'role':'system', 'content':'You are a paper abstract information extractor,
|
17 |
-
the user inputs a paper abstract, and you are responsible for extracting information. \
|
18 |
The extracted information should write in the form of: What state of the cancer (this state is usually a mutation in a driver gene) is dependent on which genes or pathways. \
|
19 |
-
Do not show other information. When there is no such information (ie. cancer is not dependent on any gene or pathway from the
|
|
|
|
|
|
|
|
|
|
|
20 |
{'role':'user', 'content':'Abstract: In non–small cell lung cancer (NSCLC), \
|
21 |
concurrent mutations in the oncogene KRAS and the tumor suppressor STK11 encoding the kinase LKB1 result in aggressive tumors \
|
22 |
prone to metastasis but with liabilities arising from reprogrammed metabolism. \
|
@@ -27,8 +32,9 @@ def get_response(text):
|
|
27 |
another nitrogen-related metabolic pathway, in both mouse and human KL mutant tumors. KL cells contain high levels of HBP metabolites, \
|
28 |
higher flux through the HBP pathway and elevated dependence on the HBP enzyme Glutamine-Fructose-6-Phosphate Transaminase 2 (GFPT2). \
|
29 |
GFPT2 inhibition selectively reduced KL tumor cell growth in culture, xenografts and genetically-modified mice. \
|
30 |
-
Our results define a new metabolic vulnerability in KL tumors and provide a rationale for targeting GFPT2 in this aggressive NSCLC subtype.'},
|
31 |
-
{'role':'assistant', 'content':'KRAS/LKB1 co-mutant non–small cell lung cancer is dependent on Hexosamine
|
|
|
32 |
{'role':'user', 'content':'Abstract: Background: Thymidylate synthase (TYMS) is a successful chemotherapeutic target for anticancer therapy. \
|
33 |
Numerous TYMS inhibitors have been developed and used for treating gastrointestinal cancer now, but they have limited clinical benefits due to \
|
34 |
the prevalent unresponsiveness and toxicity. It is urgent to identify a predictive biomarker to guide the precise clinical use of TYMS inhibitors. \
|
@@ -42,7 +48,7 @@ def get_response(text):
|
|
42 |
TYMS mRNA levels than those of progressive diseases. NIPBL inactivation decreases the therapeutic responses of \
|
43 |
gastrointestinal cancer to RTX through blocking MYC. Interpretation: Our study unveils a mechanism of how TYMS is \
|
44 |
transcriptionally regulated by MYC, and provides rationales for the precise use of TYMS inhibitors in the clinic.'},
|
45 |
-
{'role':'assistant', 'content':'Gastrointestinal cancer with up-regulated MYC is dependent on TYMS.'},
|
46 |
{'role':'user', 'content':'Abstract: Studies have characterized the immune escape landscape across primary tumors. \
|
47 |
However, whether late-stage metastatic tumors present differences in genetic immune escape (GIE) prevalence and dynamics remains unclear. \
|
48 |
We performed a pan-cancer characterization of GIE prevalence across six immune escape pathways in 6,319 uniformly processed tumor samples. \
|
@@ -52,11 +58,11 @@ def get_response(text):
|
|
52 |
in tumor evolution and focal loss of heterozygosity of HLA-I tends to eliminate the HLA allele, presenting the largest neoepitope repertoire. \
|
53 |
Finally, high mutational burden tumors showed a tendency toward focal loss of heterozygosity of HLA-I as the immune evasion mechanism, \
|
54 |
whereas, in hypermutated tumors, other immune evasion strategies prevail.'},
|
55 |
-
{'role':'assistant', 'content':'No dependency'}
|
56 |
]
|
57 |
messages.append({'role':'user', 'content':f"Abstract: {text}"})
|
58 |
response = get_completion_from_messages(messages, temperature=0)
|
59 |
-
return response
|
60 |
|
61 |
exp = [[
|
62 |
"Background: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer, \
|
@@ -92,7 +98,10 @@ def gradio():
|
|
92 |
|
93 |
output_text = gr.outputs.Textbox(label="Extracted information")
|
94 |
|
95 |
-
|
|
|
|
|
|
|
96 |
article="Example abstract from https://doi.org/10.21203/rs.3.rs-1547583/v1 and https://doi.org/10.1038/s41590-022-01129-x")
|
97 |
interface.launch()
|
98 |
|
|
|
3 |
|
4 |
openai.api_key = "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"
|
5 |
|
6 |
+
def get_completion_from_messages(messages, model="gpt-3.5-turbo-0613", temperature=0):
|
7 |
response = openai.ChatCompletion.create(
|
8 |
model=model,
|
9 |
messages=messages,
|
|
|
12 |
return response.choices[0].message["content"]
|
13 |
|
14 |
def get_response(text):
|
15 |
+
messages = [
|
16 |
+
{'role':'system', 'content':'You are a paper abstract information extractor, Your task is to perform the following actions:\
|
17 |
+
1. the user inputs a paper abstract, and you are responsible for extracting information. \
|
18 |
The extracted information should write in the form of: What state of the cancer (this state is usually a mutation in a driver gene) is dependent on which genes or pathways. \
|
19 |
+
Do not show other information. When there is no such information (ie. cancer is not dependent on any gene or pathway from the \
|
20 |
+
abstract), just return "No dependency". \
|
21 |
+
2. Format output as a json object that contains the following keys: cancer, state, gene/pathway. \
|
22 |
+
Use the following format: \
|
23 |
+
Extracted information: <Extracted information> \
|
24 |
+
Output JSON: <json with cancer, state and gene/pathway>. When there is no dependency, do not output JSON'},
|
25 |
{'role':'user', 'content':'Abstract: In non–small cell lung cancer (NSCLC), \
|
26 |
concurrent mutations in the oncogene KRAS and the tumor suppressor STK11 encoding the kinase LKB1 result in aggressive tumors \
|
27 |
prone to metastasis but with liabilities arising from reprogrammed metabolism. \
|
|
|
32 |
another nitrogen-related metabolic pathway, in both mouse and human KL mutant tumors. KL cells contain high levels of HBP metabolites, \
|
33 |
higher flux through the HBP pathway and elevated dependence on the HBP enzyme Glutamine-Fructose-6-Phosphate Transaminase 2 (GFPT2). \
|
34 |
GFPT2 inhibition selectively reduced KL tumor cell growth in culture, xenografts and genetically-modified mice. \
|
35 |
+
Our results define a new metabolic vulnerability in KL tumors and provide a rationale for targeting GFPT2 in this aggressive NSCLC subtype.'},
|
36 |
+
{'role':'assistant', 'content':'Extracted information: KRAS/LKB1 co-mutant non–small cell lung cancer is dependent on Hexosamine \
|
37 |
+
biosynthesis pathway (HBP) and GFPT2. Output JSON: {"cancer":"non–small cell lung cancer","state":"KRAS/LKB1 co-mutant","gene/pathway":"Hexosamine biosynthesis pathway (HBP) and GFPT2"}'},
|
38 |
{'role':'user', 'content':'Abstract: Background: Thymidylate synthase (TYMS) is a successful chemotherapeutic target for anticancer therapy. \
|
39 |
Numerous TYMS inhibitors have been developed and used for treating gastrointestinal cancer now, but they have limited clinical benefits due to \
|
40 |
the prevalent unresponsiveness and toxicity. It is urgent to identify a predictive biomarker to guide the precise clinical use of TYMS inhibitors. \
|
|
|
48 |
TYMS mRNA levels than those of progressive diseases. NIPBL inactivation decreases the therapeutic responses of \
|
49 |
gastrointestinal cancer to RTX through blocking MYC. Interpretation: Our study unveils a mechanism of how TYMS is \
|
50 |
transcriptionally regulated by MYC, and provides rationales for the precise use of TYMS inhibitors in the clinic.'},
|
51 |
+
{'role':'assistant', 'content':'Extracted information: Gastrointestinal cancer with up-regulated MYC is dependent on TYMS. Output JSON: {"cancer":"Gastrointestinal cancer","state":"up-regulated MYC","gene/pathway":"TYMS"}'},
|
52 |
{'role':'user', 'content':'Abstract: Studies have characterized the immune escape landscape across primary tumors. \
|
53 |
However, whether late-stage metastatic tumors present differences in genetic immune escape (GIE) prevalence and dynamics remains unclear. \
|
54 |
We performed a pan-cancer characterization of GIE prevalence across six immune escape pathways in 6,319 uniformly processed tumor samples. \
|
|
|
58 |
in tumor evolution and focal loss of heterozygosity of HLA-I tends to eliminate the HLA allele, presenting the largest neoepitope repertoire. \
|
59 |
Finally, high mutational burden tumors showed a tendency toward focal loss of heterozygosity of HLA-I as the immune evasion mechanism, \
|
60 |
whereas, in hypermutated tumors, other immune evasion strategies prevail.'},
|
61 |
+
{'role':'assistant', 'content':'Extracted information: No dependency}'}
|
62 |
]
|
63 |
messages.append({'role':'user', 'content':f"Abstract: {text}"})
|
64 |
response = get_completion_from_messages(messages, temperature=0)
|
65 |
+
return response.split("Output JSON: ")[0], json.loads(response.split("Output JSON: ")[1])
|
66 |
|
67 |
exp = [[
|
68 |
"Background: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer, \
|
|
|
98 |
|
99 |
output_text = gr.outputs.Textbox(label="Extracted information")
|
100 |
|
101 |
+
json_output = gr.JSON(label = "JSON")
|
102 |
+
|
103 |
+
interface = gr.Interface(fn=get_response, inputs=[input_text], outputs=[output_text,json_output],
|
104 |
+
examples=exp,
|
105 |
article="Example abstract from https://doi.org/10.21203/rs.3.rs-1547583/v1 and https://doi.org/10.1038/s41590-022-01129-x")
|
106 |
interface.launch()
|
107 |
|